Edwards Lifesciences (EW) Cash from Operations (2009 - 2026)

Edwards Lifesciences has reported Cash from Operations for 18 years, with the latest figure at $651.9 million in Q2 2026.

• On a quarterly basis, Cash from Operations rose 124.64% year-over-year to $651.9 million in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 116.42% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 194.15% from the prior year.
• Cash from Operations was $651.9 million for Q2 2026 at Edwards Lifesciences, up from $43.8 million in the prior quarter.
• The five-year high for Cash from Operations was $651.9 million in Q2 2026, with the low at -$127.5 million in Q4 2024.
• Average Cash from Operations over 5 years is $274.8 million, with a median of $301.6 million recorded in 2022.
• The largest YoY upside for Cash from Operations was 1005.65% in 2024 against a maximum downside of 193.34% in 2024.
• Over 5 years, Cash from Operations stood at $282.8 million in 2022, then plunged by 51.7% to $136.6 million in 2023, then slumped by 193.34% to -$127.5 million in 2024, then surged by 453.65% to $450.9 million in 2025, then surged by 44.58% to $651.9 million in 2026.
• The last three Cash from Operations figures came in at $651.9 million (Q2 2026), $43.8 million (Q1 2026), and $450.9 million (Q4 2025), per Business Quant data.